ASRT Quote, Financials, Valuation and Earnings

ANI Pharmaceuticals, Inc. has a net margin of 23.14% compared to Assertio Holdings, Inc.'s net margin of 10.28%. Assertio Holdings, Inc.'s return on equity of -25.86% beat ANI Pharmaceuticals, Inc.'s return on equity of 15.48%.

Assertio Holdings, Inc. has a consensus price target of $39.94, signalling upside risk potential of 243.7%. On the other hand ANI Pharmaceuticals, Inc. has an analysts' consensus of $110.63 which suggests that it could grow by 52.61%. Given that Assertio Holdings, Inc. has higher upside potential than ANI Pharmaceuticals, Inc., analysts believe Assertio Holdings, Inc. is more attractive than ANI Pharmaceuticals, Inc..

Assertio Holdings, Inc. has a beta of 0.728, which suggesting that the stock is 27.176% less volatile than S&P 500. In comparison ANI Pharmaceuticals, Inc. has a beta of 0.521, suggesting its less volatile than the S&P 500 by 47.912%.

Assertio Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ANI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Assertio Holdings, Inc. pays -- of its earnings as a dividend. ANI Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Assertio Holdings, Inc. quarterly revenues are $49.5M, which are smaller than ANI Pharmaceuticals, Inc. quarterly revenues of $247.1M. Assertio Holdings, Inc.'s net income of $11.4M is lower than ANI Pharmaceuticals, Inc.'s net income of $25.4M. Notably, Assertio Holdings, Inc.'s price-to-earnings ratio is -- while ANI Pharmaceuticals, Inc.'s PE ratio is 21.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Assertio Holdings, Inc. is 4.33x versus 1.71x for ANI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Aura Biosciences, Inc. has a net margin of 23.14% compared to Assertio Holdings, Inc.'s net margin of --. Assertio Holdings, Inc.'s return on equity of -25.86% beat Aura Biosciences, Inc.'s return on equity of -67.74%.

Assertio Holdings, Inc. has a consensus price target of $39.94, signalling upside risk potential of 243.7%. On the other hand Aura Biosciences, Inc. has an analysts' consensus of $20.20 which suggests that it could grow by 239.5%. Given that Assertio Holdings, Inc. has higher upside potential than Aura Biosciences, Inc., analysts believe Assertio Holdings, Inc. is more attractive than Aura Biosciences, Inc..

Assertio Holdings, Inc. has a beta of 0.728, which suggesting that the stock is 27.176% less volatile than S&P 500. In comparison Aura Biosciences, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Assertio Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aura Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Assertio Holdings, Inc. pays -- of its earnings as a dividend. Aura Biosciences, Inc. pays out -- of its earnings as a dividend.

Assertio Holdings, Inc. quarterly revenues are $49.5M, which are larger than Aura Biosciences, Inc. quarterly revenues of --. Assertio Holdings, Inc.'s net income of $11.4M is higher than Aura Biosciences, Inc.'s net income of -$26.1M. Notably, Assertio Holdings, Inc.'s price-to-earnings ratio is -- while Aura Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Assertio Holdings, Inc. is 4.33x versus -- for Aura Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Catalyst Pharmaceuticals, Inc. has a net margin of 23.14% compared to Assertio Holdings, Inc.'s net margin of 34.53%. Assertio Holdings, Inc.'s return on equity of -25.86% beat Catalyst Pharmaceuticals, Inc.'s return on equity of 25.2%.

Assertio Holdings, Inc. has a consensus price target of $39.94, signalling upside risk potential of 243.7%. On the other hand Catalyst Pharmaceuticals, Inc. has an analysts' consensus of $34.00 which suggests that it could grow by 45.36%. Given that Assertio Holdings, Inc. has higher upside potential than Catalyst Pharmaceuticals, Inc., analysts believe Assertio Holdings, Inc. is more attractive than Catalyst Pharmaceuticals, Inc..

Assertio Holdings, Inc. has a beta of 0.728, which suggesting that the stock is 27.176% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals, Inc. has a beta of 0.746, suggesting its less volatile than the S&P 500 by 25.388%.

Assertio Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Assertio Holdings, Inc. pays -- of its earnings as a dividend. Catalyst Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Assertio Holdings, Inc. quarterly revenues are $49.5M, which are smaller than Catalyst Pharmaceuticals, Inc. quarterly revenues of $152.6M. Assertio Holdings, Inc.'s net income of $11.4M is lower than Catalyst Pharmaceuticals, Inc.'s net income of $52.7M. Notably, Assertio Holdings, Inc.'s price-to-earnings ratio is -- while Catalyst Pharmaceuticals, Inc.'s PE ratio is 13.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Assertio Holdings, Inc. is 4.33x versus 5.05x for Catalyst Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Castle Biosciences, Inc. has a net margin of 23.14% compared to Assertio Holdings, Inc.'s net margin of -2.68%. Assertio Holdings, Inc.'s return on equity of -25.86% beat Castle Biosciences, Inc.'s return on equity of -5.28%.

Assertio Holdings, Inc. has a consensus price target of $39.94, signalling upside risk potential of 243.7%. On the other hand Castle Biosciences, Inc. has an analysts' consensus of $48.50 which suggests that it could grow by 91.55%. Given that Assertio Holdings, Inc. has higher upside potential than Castle Biosciences, Inc., analysts believe Assertio Holdings, Inc. is more attractive than Castle Biosciences, Inc..

Assertio Holdings, Inc. has a beta of 0.728, which suggesting that the stock is 27.176% less volatile than S&P 500. In comparison Castle Biosciences, Inc. has a beta of 1.088, suggesting its more volatile than the S&P 500 by 8.781%.

Assertio Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Castle Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Assertio Holdings, Inc. pays -- of its earnings as a dividend. Castle Biosciences, Inc. pays out -- of its earnings as a dividend.

Assertio Holdings, Inc. quarterly revenues are $49.5M, which are smaller than Castle Biosciences, Inc. quarterly revenues of $87M. Assertio Holdings, Inc.'s net income of $11.4M is higher than Castle Biosciences, Inc.'s net income of -$2.3M. Notably, Assertio Holdings, Inc.'s price-to-earnings ratio is -- while Castle Biosciences, Inc.'s PE ratio is 30.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Assertio Holdings, Inc. is 4.33x versus 2.14x for Castle Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.